Indaptus Therapeutics, Inc. (INDP)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$18.0M
Cash & Equivalents
$7.0M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$298M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-06-30 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05651022 Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors PHASE2 Active Not Recruiting 120

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for INDP.

SEC EDGAR Filings

All SEC filings for Indaptus Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.